Overview
- Editors:
-
-
Véronique Leblond
-
Haematology, Hôpital Pitié-Salpêtriêre, Paris, France
-
Steve Treon
-
Dana Farber Cancer Institute, Boston, USA
-
Meletios Dimoploulos
-
School of Medicine, University of Athens, Athens, Greece
- Timely international book on this rare disease
- Brings updates on clinical, biological and therapeutic data
- Edited by the three world experts with contributions from high-profile authors, world leaders in their field
Access this book
Other ways to access
Table of contents (26 chapters)
-
-
Tumor Cells and Microenvironment
-
-
- Roger G. Owen, Andy C. Rawstron, Ruth M. de Tute
Pages 3-19
-
- Noemí Puig, Enrique M. Ocio, Cristina Jiménez, Bruno Paiva, Jesús F. San Miguel, Ramón García-Sanz
Pages 21-34
-
- Linda M. Pilarski, Jitra Kriangkum, Sophia Adamia, Helga M. Ogmundsdottir, Andrew R. Belch
Pages 35-48
-
-
- Zachary R. Hunter, Guang Yang, Lian Xu, Xia Liu, Jorge J. Castillo, Steven P. Treon
Pages 53-65
-
- Antonio Sacco, Michele Moschetta, Salomon Manier, Giuseppe Rossi, Irene M. Ghobrial, Aldo M. Roccaro
Pages 67-71
-
- Efstathios Kastritis, Aldo Roccaro, Magdalini Migou, Irene Ghobrial
Pages 73-82
-
- D. E. Joshua, R. Brown, P. J. Ho, J. Gibson, H. Suen
Pages 83-94
-
Epidemiology and Genetic Predisposition
-
-
- Vilhjálmur Steingrímsson, Ola Landgren, Sigurður Yngvi Kristinsson
Pages 97-109
-
- Mary L. McMaster, Helga M. Ögmundsdóttir
Pages 111-141
-
- Mary L. McMaster, Helga M. Ögmundsdóttir, Sigurdur Y. Kristinsson, Robert A. Kyle
Pages 143-167
-
Clinical Features
-
Front Matter
Pages 169-169
-
- Marvin J. Stone, Sigbjorn Berentsen
Pages 171-183
-
- Karine Viala, Michael Lunn
Pages 185-194
-
- Morie A. Gertz, Taimur Sher, Angela Dispenzieri, Francis K. Buadi
Pages 195-207
-
- K. Ina Ly, Florian Fintelmann, Reza Forghani, Ephraim P. Hochberg, Fred H. Hochberg
Pages 209-221
-
- Giampaolo Merlini, Bouchra Asli, Jean-Paul Fermand
Pages 223-236
About this book
This book sheds new light on clinical, biological and therapeutic data on the rare disease Waldenström’s Macroglobulinemia (WM) with the participation of widely-recognized experts, involved in this field. It represents the efforts of physicians, scientists and patients, all around the world, to better understand and cure this rare disease.
Considerable advances in the diagnosis, treatment indications, response criteria, prognostic factors and treatment options have been made since Dr Jan Waldenström first reported this “new syndrome“ 70 years ago. Particularly instrumental in advancing of our understanding of WM have been the eight international workshops devoted to this disease. New, exciting molecular data have recently been reported, allowing us to revisit the oncogenic events leading to WM B-cell proliferation and to use newly available compounds targeting oncogenic pathways.
Editors and Affiliations
-
Haematology, Hôpital Pitié-Salpêtriêre, Paris, France
Véronique Leblond
-
Dana Farber Cancer Institute, Boston, USA
Steve Treon
-
School of Medicine, University of Athens, Athens, Greece
Meletios Dimoploulos
About the editors
Véronique Leblond, Professor in Hematology, is the head of the department of Hematology at Pitié Salpêtrière Hospital, Paris, France. She is the chair of the “French Cooperative Group on Chronic Lymphocytic Leukemia and Waldenström’s Macroglobulinemia: FCG CLL-WM” including more than 90 centers in France and Belgium. She is responsible for a rare tumor network (K-VIROGREF) dedicated to the management of transplant recipients with virus-induced tumors and funded by the French national Institute for cancer in 2012. The team historically focuses on chronic B-cell lymphoproliferative disorders, amyloidosis, on ocular and CNS lymphoma and on lymphoproliferations in immunosuppressed patients (HIV, organ-transplanted patients). She is the head of GRECHY, affiliated to the PhD school ED394 “Physiology & Physio-pathology”. Steven Treon is the Director of the Bing Center for Waldenström’s Research and an attending physician for medical oncology, at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, in Boston, Massachusetts. He is also an Associate Professor of Medicine at Harvard Medical School in Boston, and is the Chair of the Waldenström's Macroglobulinemia Clinical Trials Group. Dr Treon’s main research interests focus on understanding the genetic basis and pathogenesis of Waldenström’s macroglobulinemia and the development of therapeutics for this malignancy. Meletios A. Dimopoulos, MD is Professor and Chairman of the Department of Clinical Therapeutics at the University Athens School of Medicine, Athens, Greece. He is a member of numerous scientific societies and has authored more than 650 publications (April 2013) in peer-reviewed journals. Dr. Dimopoulos serves on the Scientific Advisory Boards of the Multiple Myeloma Research Foundation, of the International Myeloma Foundation, of the International Waldenstrom’s Macroglobulinemia Foundation and he is a member of the Board of the European Myeloma Network.
